Royalty Pharma (RPRX) Amortization - Intangibles (2019 - 2022)

Royalty Pharma (RPRX) has 4 years of Amortization - Intangibles data on file, last reported at $5.7 million in Q1 2022.

• For the quarter ending Q1 2022, Amortization - Intangibles changed 0.02% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2022 stood at $5.7 million (down 75.34% YoY), and the FY2022 full-year result was $5.7 million, down 75.34% from the prior year.
• Amortization - Intangibles retreated to $5.7 million in Q1 2022, from $5.8 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $5.8 million in Q3 2019 to a low of $5.7 million in Q1 2022.
• A 4-year average of $5.8 million and a median of $5.8 million in 2019 frame the typical range for Amortization - Intangibles.
• Across the five-year window, Amortization - Intangibles changed 0.0% in 2020 and retreated 1.08% in 2021, its largest moves.
• Tracing RPRX's Amortization - Intangibles over 4 years: stood at $5.8 million in 2019, then changed by 0.0% to $5.8 million in 2020, then changed by 0.0% to $5.8 million in 2021, then decreased by 2.17% to $5.7 million in 2022.
• Business Quant data shows RPRX's Amortization - Intangibles at $5.7 million in Q1 2022, $5.8 million in Q4 2021, and $5.8 million in Q3 2021.